Cancer research: molecular machinery critical for cell's ability to move identified

December 17, 2019

Many cells in our body constantly change their shape and move within our tissues. For example, wound healing and the immune system depend on migrating cells. On the other hand, uncontrolled cell migration is a hallmark of metastasis during the development of malignant cancers, so cell migration must be very tightly regulated.

The driving force for cell migration is produced by a protein called actin. Actin monomers act as building blocks by polymerising into rod-like filaments that push the leading edge of the cell forward. The polymerisation of the actin filaments must be balanced by depolymerisation of the filaments at the other end.

Now, scientists at the University of Helsinki, Finland, and Institut Jacques Monod, France, have identified a molecular machinery which drives rapid depolymerisation of actin filaments and recycles the resulting actin monomers for a new round of polymerisation. Two proteins, cyclase-associated protein and cofilin, work together in this.

"By using X-ray crystallography and computer simulations, we could actually see the atomic details of how these two proteins embrace actin filaments and disassemble them into their building blocks. One of the most exciting parts of the project was to see under the microscope how actin filaments suddenly began disappearing when we introduced these two proteins into their vicinity," says PhD student Tommi Kotila, the lead author of the study.

In malignant tumours, cells go haywire in their movements, because their migration machinery is not properly controlled. Because, in cancer cells, the regulation of cyclase-associated protein is often defective, the atomistic structure of this machinery may open new avenues for developing therapeutics to inhibit cell migration in cancer.

"This is a great contribution to our understanding of the basic principles of cell migration. It also helps us understand the molecular basis of the uncontrolled migration of cancer cells," says academy professor Pekka Lappalainen.
-end-
The study was carried out as a collaboration between the laboratories of Pekka Lappalainen and Ilpo Vattulainen at the University of Helsinki, and Guillaume Romet-Lemonne and Antoine Jégou at the Jacques Monod Institute, Paris, France.

University of Helsinki

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.